AR065921A1 - Anticuerpos anti-ige - Google Patents

Anticuerpos anti-ige

Info

Publication number
AR065921A1
AR065921A1 ARP080101376A ARP080101376A AR065921A1 AR 065921 A1 AR065921 A1 AR 065921A1 AR P080101376 A ARP080101376 A AR P080101376A AR P080101376 A ARP080101376 A AR P080101376A AR 065921 A1 AR065921 A1 AR 065921A1
Authority
AR
Argentina
Prior art keywords
ige
human
less measured
rbl
recombined
Prior art date
Application number
ARP080101376A
Other languages
English (en)
Inventor
Sirid-Aimee Kellermann
Wei Liao
Mike Yeadon
Alison Logan
Mark Moffat
Caroline Brown
Wai Liu
Isabelle De Mendez
Gerald Casperson
Arvind Rajpal
Original Assignee
Amgen Fremont Inc
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Fremont Inc, Pfizer filed Critical Amgen Fremont Inc
Publication of AR065921A1 publication Critical patent/AR065921A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Composiciones farmacéuticas y métodos para el tratamiento del asma, en particular asma alérgica, así como otros trastornos donde interviene la IgE que incluyen rinitis alérgica y alergias alimentarias. Reivindicacion 1: Un anticuerpo monoclonalhumano, o una porcion de éste de union al antígeno dirigido contra la IgE humana, o una porcion de éste de union al antígeno, caracterizado porque tiene al menos una propiedad adicional seleccionada del grupo que consiste en: a) tiene un valor deCI50 de 0,5 mg/ml o menor medido por su capacidad para reducir el ensayo de union a la célula IgE utilizando una línea celular RBL-2H3 transfectada con el Fc?R1 humano; b) tiene un valor de CI50 de 0,5 mg/ml o menor medido por su capacidad parainhibir la desgranulacion en donde interviene la IgE utilizando una línea celular RBL-2H3 transfectada con el Fc?R1 humano, c) no se entrecruza con la IgE unida al receptor y no estimula la desgranulacion en que interviene la IgE de las células RBL-2H3 (Fc?R1) cultivadas con la IgE humana; d) no se entrecruza con la IgE unida al receptor y no estimula la desgranulacion en que interviene la IgE de basofilos de sangre humana; e) son muy selectivos para la IgE sobre IgA, IgG1 y IgG3 humanas, f)se une a la longitud total de IgE humana con una constante de afinidad, KD, de 15 nM o menor medida por resonancia de plasmon superficial; g) tiene una disociacion (kOff) para la IgE humana de 2 x 10-4 s-1 o menor medida por resonancia de plasmonsuperficial; h) se une al mismo epítopo de la IgE humana como un anticuerpo seleccionado del grupo que consiste en 5.396.1 recombinado; 5.396.1 Hc-S103N Lc-K61R; 6.605.1 recombinado; 6.605.1 (H3Q, M13K, D82E-T25A, T53S); 5.948.1. recombinado, y5.948.1 H100Y.
ARP080101376A 2007-04-02 2008-04-01 Anticuerpos anti-ige AR065921A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92154607P 2007-04-02 2007-04-02
US875507P 2007-12-20 2007-12-20

Publications (1)

Publication Number Publication Date
AR065921A1 true AR065921A1 (es) 2009-07-08

Family

ID=39831518

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101376A AR065921A1 (es) 2007-04-02 2008-04-01 Anticuerpos anti-ige

Country Status (21)

Country Link
US (2) US7867494B2 (es)
EP (1) EP2142214A4 (es)
JP (1) JP2010532158A (es)
KR (1) KR20100018499A (es)
CN (1) CN101808661A (es)
AR (1) AR065921A1 (es)
AU (1) AU2008236765A1 (es)
BR (1) BRPI0809677A2 (es)
CA (1) CA2682927A1 (es)
CL (1) CL2008000935A1 (es)
DO (1) DOP2008000018A (es)
GT (1) GT200800034A (es)
IL (1) IL201156A0 (es)
MX (1) MX2009010765A (es)
PA (1) PA8775101A1 (es)
PE (1) PE20081899A1 (es)
RU (1) RU2009140313A (es)
SG (1) SG182985A1 (es)
TW (1) TW200904470A (es)
UY (1) UY30994A1 (es)
WO (1) WO2008123999A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2624081C (en) 2005-09-29 2014-09-16 Medimmune, Inc. Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
HUE042901T2 (hu) * 2008-09-17 2019-07-29 Xencor Inc Készítmények és eljárások IgE által közvetített rendellenességek kezelésére
ES2622562T3 (es) 2008-12-09 2017-07-06 Pfizer Vaccines Llc Vacuna de péptido CH3 de IgE
KR20110139292A (ko) * 2009-04-20 2011-12-28 화이자 인코포레이티드 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법
WO2010128265A2 (fr) 2009-05-07 2010-11-11 Stallergenes S.A. Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US10017762B2 (en) * 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
EP2699603B1 (en) 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
WO2013119419A1 (en) * 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
CA2863714C (en) * 2012-02-08 2022-07-05 Igm Biosciences, Inc. Cdim binding proteins and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP6671298B2 (ja) 2014-05-16 2020-03-25 アムジェン インコーポレイテッド Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ
JP6519913B2 (ja) * 2015-02-05 2019-05-29 国立大学法人名古屋大学 ＩｇＥ結合性エピトープペプチドの利用
US10293059B2 (en) * 2015-04-09 2019-05-21 Cornell University Gene therapy to prevent reactions to allergens
CN107921127B (zh) * 2015-05-22 2022-04-08 纪念斯隆-凯特琳癌症中心 对于prame肽具有特异性的t细胞受体样抗体
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN107686521B (zh) * 2016-08-04 2021-04-06 越海百奥药业(绍兴)有限公司 一种人源化抗IgE单克隆抗体
CA3041717A1 (en) * 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
EP3565587A4 (en) 2017-01-06 2020-12-16 The Regents of The University of California THERAPEUTIC ANTI-IGE ANTIBODIES AND RELATED METHODS AND COMPOSITIONS
SG11201908328XA (en) 2017-03-14 2019-10-30 Amgen Inc Control of total afucosylated glycoforms of antibodies produced in cell culture
BR112020019559A2 (pt) 2018-03-26 2021-01-12 Amgen Inc. Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
AU2020376934A1 (en) * 2019-11-01 2022-06-02 Vor Biopharma, Inc. Anti-CD45 antibodies and conjugates thereof
CN113372450A (zh) * 2020-03-10 2021-09-10 北京万华生物工程有限公司 IgE嵌合性双特异性抗体制备及应用
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
KR102545843B1 (ko) * 2021-02-24 2023-06-20 주식회사 세바바이오텍 알러지, 아토피 및 가려움 개선용 기능성 소재의 스크리닝 방법
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
WO1992017207A1 (en) * 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
WO1992021031A1 (en) * 1991-05-10 1992-11-26 Alain De Weck PROCEDURE FOR DETECTING AND PREPARING ANTI-IgE AUTOANTIBODIES AND USE OF THESE ANTIBODIES AS ACTIVE AGENTS IN DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993019197A1 (en) * 1992-03-20 1993-09-30 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
WO1996033266A1 (en) 1995-04-21 1996-10-24 Cell Genesys, Inc. Generation of large genomic dna deletions
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
JP2002505097A (ja) 1998-03-03 2002-02-19 アブジェニックス インク． 治療薬としてのｃｄ１４７結合分子
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
RS51309B (sr) 1998-12-23 2010-12-31 Pfizer Inc. Humana monoklonalna antitela za ctla-4
KR20020086893A (ko) * 2000-01-14 2002-11-20 다이이치세이야꾸 가부시끼가이샤 신규 펩티드 및 그것을 이용한 스크리닝 방법
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes
PE20080035A1 (es) * 2005-09-07 2008-01-30 Amgen Fremont Inc Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina

Also Published As

Publication number Publication date
JP2010532158A (ja) 2010-10-07
US20090117124A1 (en) 2009-05-07
MX2009010765A (es) 2009-10-26
US7867494B2 (en) 2011-01-11
SG182985A1 (en) 2012-08-30
AU2008236765A1 (en) 2008-10-16
CL2008000935A1 (es) 2008-11-07
GT200800034A (es) 2010-03-16
RU2009140313A (ru) 2011-05-10
EP2142214A4 (en) 2012-03-21
UY30994A1 (es) 2008-11-28
KR20100018499A (ko) 2010-02-17
PA8775101A1 (es) 2008-11-19
WO2008123999A9 (en) 2009-12-10
CN101808661A (zh) 2010-08-18
BRPI0809677A2 (pt) 2014-10-07
PE20081899A1 (es) 2009-01-26
DOP2008000018A (es) 2008-10-15
US20110064726A1 (en) 2011-03-17
TW200904470A (en) 2009-02-01
EP2142214A2 (en) 2010-01-13
IL201156A0 (en) 2010-05-17
WO2008123999A2 (en) 2008-10-16
WO2008123999A3 (en) 2010-06-24
CA2682927A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
AR065921A1 (es) Anticuerpos anti-ige
PE20060376A1 (es) ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3
RU2474588C2 (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
BRPI0614040B8 (pt) anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo
MY153893A (en) Antibodies against human il17 and uses thereof
CL2008002565A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente al dominio extracelular de cxcr5/receptor de linfoma de burkitt (blr1)/cd185/mdr15/mgc117347 humano; molécula de ácido nucleico aislada que lo codifica; vector que comprende a dicha molécula de ácido nucleico; célula huésped aislada que comprende a dicho vector; uso médico de dicho anticuerpo; y composición farmacéutica que lo comprende.
AR064109A1 (es) Anticuerpos humanos que se enlazan al cd22 y sus usos
UA109633C2 (uk) Антитіло людини проти тканинного фактора
PE20081186A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
BRPI0607486B8 (pt) anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
AR063829A1 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
PE20090689A1 (es) Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
AR058104A1 (es) Compuestos organicos
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
UA116614C2 (uk) Антитіло до фактора d і його застосування
AR059604A1 (es) Anticuerpos contra il- 22 humana y usos para los mismos
BRPI0513078B8 (pt) anticorpo igg que se liga a il-17 humana e composição líquida
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
AR058955A1 (es) Inmunglobulinas que se unen a interleuquina 13
CL2013003244A1 (es) Anticuerpo monoclonal que se une especificamente a la proteina rgm; acido nucleico aislado que lo codifica; vector; celula huesped, metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar enfermedades neurologicas (div. sol.n°459-09)
ATE492561T1 (de) Verbesserte protofibrilselektive antikörper und deren verwendung
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
BRPI0611414B8 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos
ECSP099645A (es) Anticuerpos anti ige apoptóticos
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma

Legal Events

Date Code Title Description
FA Abandonment or withdrawal